Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to $5.8 million.

  • Envoy Medical's Operating Expenses rose 1435.96% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year decrease of 491.5%. This contributed to the annual value of $19.5 million for FY2024, which is 431.59% up from last year.
  • Per Envoy Medical's latest filing, its Operating Expenses stood at $5.8 million for Q3 2025, which was up 1435.96% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's Operating Expenses registered a high of $6.8 million during Q4 2023, and its lowest value of $901356.0 during Q2 2022.
  • For the 4-year period, Envoy Medical's Operating Expenses averaged around $4.1 million, with its median value being $4.6 million (2024).
  • As far as peak fluctuations go, Envoy Medical's Operating Expenses skyrocketed by 40401.84% in 2023, and later plummeted by 3266.35% in 2024.
  • Quarter analysis of 4 years shows Envoy Medical's Operating Expenses stood at $2.9 million in 2022, then surged by 133.01% to $6.8 million in 2023, then tumbled by 32.66% to $4.6 million in 2024, then rose by 25.25% to $5.8 million in 2025.
  • Its Operating Expenses stands at $5.8 million for Q3 2025, versus $5.1 million for Q2 2025 and $5.2 million for Q1 2025.